explore -WSS

explore

author：entertainment 2025-10-02 23:31:24 - browse：71

Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.

For more on what we cover, here’s more on Gilead; here’s the news on Inhibrx; here’s the latest on biotech venture capital; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medicare details structure of new drug price negotiation program
Next article： Dewpoint Therapeutics lays off staff after losing partnerships

leisure time

knowledge

WSS

Eli Lilly, Pfizer, and others want in on the online prescription market

New brain studies show LSD's effects on the brain in full color

How digital therapeutics firms are pivoting after Pear's bankruptcy

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

UPS workers' union leader explains what's at stake as strike edges closer

California man arrested in connection with serial murders of Mexican strip club workers

explore

explore

explore

Alkermes shareholders re

New brain studies show LSD's effects on the brain in full color

In Memoriam: Notable people who died in 2023

FDA clears AI tool for detecting skin cancer

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Merck, J&J, and long Covid

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Jerome Adams on the need for new antivirals for Covid

FDA approves Leqembi, a milestone in Alzheimer’s treatment

focus

Elizabeth Holmes banned from government health programs

North Korean leader's powerful sister says warplanes repelled US spy plane

Readout Newsletter: Merck, J&J, and long Covid

Another man arrested in connection with shooting at Kansas nightclub

AI generated plenty of interest at JPM but not a lot of trust

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

hotspot

leisure time

knowledge

hotspot